Nautilus Biotechnology Q3 net loss $15.9M, op ex up 21% YoY to $19.1M

Nautilus Biotechnology, Inc.

2023-Q3 EPS reported -$0.37

Net loss of $15.9M for Q3 2023 vs. $14.1M in Q3 2022.
Operating expenses rose 21% YoY to $19.1M, driven by increased headcount for product development.
Cash, cash equivalents and investments totaled $275.7M as of Sept. 30, 2023.
Company reiterates focus on commercial platform launch in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nautilus Biotechnology, Inc. reported the third quarter ended September 30, 2023 results: net income $15.9 million.

Period: the third quarter ended September 30, 2023
Net income: $15.9 million
Result: reported results

Exact text from the filing

Net loss was $15.9 million for the third quarter of 2023, as compared to a net loss of $14.1 million for the corresponding prior year period.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-23-000073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.